No Data
No Data
Down -17.96% in 4 Weeks, Here's Why Revance Therapeutics (RVNC) Looks Ripe for a Turnaround
Top Premarket Decliners
Express News | Revance Therapeutics-Co’s Ongoing Discussions With Teoxane and Buyer Parties Could Result in Delays to Consummation of Offer
Express News | Revance Therapeutics- on Aug 16, Co Got Notice to Remedy Alleged Material Breaches, Under Co’s Exclusive Distribution Deal With Teoxane SA
Deals This Week: Smartsheet, AT&T, BP, Cleveland-Cliffs, Vistra and More
Guggenheim Downgrades Revance Therapeutics(RVNC.US) to Hold Rating, Cuts Target Price to $6.66
No Data
No Data